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I
think it’s remarkable that only a few months after
Banting introduced insulin to the world of diabetes,
on the heels of one of medicine’s greatest discover-
ies, Elliot Joslin wrote, “insulin is not a cure for
diabetes, but a potent preparation alike...f o revil and for
good.” Today, 85 years later, with all the advances in
insulin therapy, there is still a dark side to this potent
preparation, and it is hypoglycemia. Hypoglycemia is the
major barrier preventing insulin from achieving its full,
therapeutic promise.
My story begins 30 years ago. Bill Tamborlane came to
me with a portable, battery-powered pump being used in
pediatrics to infuse the iron-chelating drug desferrioxam-
ine continuously via the subcutaneous route into children
with thalassemia major. He hoped to use it to treat
children with glycogen storage disease, a study we never
performed. This relatively small pump, the Autosyringe
Model AS2C, was at that time relatively unique. It had an
“instant dose” button that allowed for bolus dose admin-
istration as well as the ability to deliver solutions contin-
uously. In short, it was a “perfect” vehicle to infuse insulin
in diabetes. Improved glucose control had been demon-
strated earlier in the inpatient setting in type 1 diabetic
patients given continuous intravenous insulin delivered at
preprogrammed basal rates with increments before meals.
Such systems were not practical outside of a controlled
environment. This device, however, was small enough to
be used for continuous subcutaneous insulin delivery.
My enthusiasm for this idea was based on experiments
Luigi Sacca and I performed 2 years earlier in the mid
1970s. We demonstrated that overnight basal insulin infu-
sion in doses sufﬁcient to normalize fasting glucose the
next morning restored the ability of hyperglycemia to
suppress hepatic glucose production in type 1 diabetic
patients, despite their failure to release insulin (1). Those
studies suggested that if insulin were delivered at more
physiological basal rates (something that was not easy to
achieve with the intermediate-acting insulin available at
the time), it would not only provide better regulation of
fasting glucose but also minimize postprandial hypergly-
cemia after a breakfast meal. The second study made me
think that open-loop continuous insulin delivery might be
relatively safe. In that study, we infused insulin to “con-
ventionally” (which at that time was poorly) treated type 1
diabetic subjects in doses that approached 2 units/h (2).
Only mild hypoglycemia (59  5 mg/dl) was produced;
glucose stabilized at levels comparable with those seen in
nondiabetic control subjects. Since these doses of insulin
exceed usual basal requirements overnight, I assumed that
if insulin were delivered continuously by the subcutaneous
route in relatively small basal doses, even if dosage errors
occurred and plasma glucose fell during sleep, the patient
would still be able to muster adequate counterregulatory
defenses to protect against severe hypoglycemia.
Our initial inpatient insulin pump studies conducted by
Bill Tamborlane and our team of dedicated nurses were
highly successful and were trumpeted in the New York
Times. The “insulin pump” produced near normalization of
blood glucose throughout the day and night in youngsters
with type 1 diabetes that had been difﬁcult to control
outside of the hospital (3). The improvement in glucose
regulation with the pump was achieved without an
increase in daily insulin doses and was associated with
improved lipid and protein metabolism as well as
growth potential (4,5). We saw these studies as conﬁrm-
ing the idea that such an approach would not promote
excessive hypoglycemia and said so in our report in
1979 (3): “Noteworthy, was the fact that mean concen-
trations, as well as ﬂuctuations in plasma glucose, were
reduced without the development of chemical, or clini-
cal hypoglycemia ....T h efailure to observe hypoglyce-
mia during treatment with the infusion pump, may be
related to the physiologic nature of between-meal basal
insulin administration.”
This conclusion, unfortunately, proved incorrect. After
our patients left the hospital, while this “more physiolog-
ical” insulin delivery system markedly improved glycemic
control (6) and prompted longer-term collaborative clini-
cal trials (7), it did not take long for the dark side of
insulin, hypoglycemia, appeared. Contrary to our optimis-
tic predictions, patients had frequent hypoglycemia, and to
our surprise, frequently they were totally unaware of it. As
with many “new” clinical observations, they are often not
as new as they seemed. Fredrick Banting in his 1925 Nobel
Laureate lecture stated, “The level at which hypoglycemic
symptoms occur, is slightly higher in the diabetic with
marked hyperglycemia....A sapatient becomes accus-
tomed to a normal blood glucose, the threshold of these
reactions, becomes lower.”
The importance of hypoglycemia, as a complication of
intensive insulin therapy, became fully apparent when the
beneﬁts of such treatment in the Diabetes Control and
Complications Trial (DCCT) were announced, more than a
decade later (8). The DCCT follow-up analysis (9) showed
that one-half of severe hypoglycemic events occurred
while patients were asleep. In those patients who were
awake at the time of the hypoglycemic event, one-half
were not aware of impeding hypoglycemia and therefore
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for many patients, the immediate fear of severe hypo-
glycemia exceeds the fear of long-term diabetes complica-
tions. This reduces the commitment of patients, their
families, and their physicians to intensive insulin treatment.
The reason for the higher rate of hypoglycemia became
evident when we adapted the euglycemic-hyperinsuline-
mic clamp for studies of hypoglycemia. This technique,
developed a decade earlier when I worked as a postdoc-
toral fellow in the laboratory of Reuben Andres (10),
allowed us to produce a standardized hypoglycemic stim-
ulus, providing a means to compare responses between
nondiabetic and diabetic subjects (11,12). These studies
taught us that nondiabetic subjects are exquisitely sensi-
tive to very small reductions in circulating glucose. When
glucose falls below 80 mg/dl, endogenous insulin secretion
is nearly totally suppressed. A further decline below 70
mg/dl provokes glucagon and epinephrine secretion, the
two hormones most critical for the rapid restoration of
blood glucose, whereas a decline to below 55–60 mg/dl
produces symptoms. This multihormonal hypoglycemia
defense system is severely compromised in type 1 diabe-
tes, even in the absence of intensive insulin treatment.
These patients, by deﬁnition, are unable to shut off the
delivery of endogenous insulin into the portal circulation,
and more importantly, they fail to secrete glucagon spe-
ciﬁcally when they need it most, during hypoglycemia (at
other times glucagon secretion may be inappropriately
excessive). This poorly understood defect, originally re-
ported by Jack Gerich (13), makes type 1 diabetic patients
totally dependent on epinephrine for their defense against
hypoglycemia. Unexpectedly, we found that this alterna-
tive defense is compromised in many patients within a
short time after initiating intensive insulin therapy. Epi-
nephrine release, and the appearance of symptoms, only
occurred when plasma glucose reached dangerously low
levels, commonly below 50 mg/dl (Fig. 1). Thus, loss of
symptom awareness was linked to a lowering of the
glucose level required to trigger epinephrine secretion.
Complementary experiments by Stephanie Amiel, then a
postdoctoral fellow in the lab, showed that the impairment
of glucose counterregulation induced by intensive insulin
treatment interfered with the ability of patients to effec-
tively counteract even relatively small doses of infused
insulin (14). As we observed earlier (2), when insulin was
infused continuously in relatively low doses, convention-
ally treated type 1 diabetic patients were indeed able to
defend against severe hypoglycemia. However, after
insulin pump therapy, their response changed. They
developed severe hypoglycemia due to the combined
effects of inadequate release of epinephrine and im-
proved insulin sensitivity.
It is noteworthy that the levels of glucose bathing the
brain are very different from those we measure in the
systemic circulation. Remarkably, glucose levels in human
brain interstitial ﬂuid during hypoglycemia are only 25%
of those measured in plasma (15). As a result, brain
glucose may fall to concentrations that are rate limiting for
glucose metabolism in areas of brain in which activity is
locally increased. For glucose, there really is a blood-brain
barrier.
The reason that severe hypoglycemia most commonly
occurred during sleep in the DCCT became apparent when
Tim Jones performed hypoglycemic clamp experiments
during the day and in the middle of the night (16). At night,
nondiabetic and diabetic subjects were studied both while
awake and while asleep. As expected, hypoglycemia pro-
voked epinephrine release when subjects were awake,
independent of the time of day. In striking contrast, the
same hypoglycemic stimulus had little effect on epineph-
rine release when either group of subjects was asleep. It
took a much greater glucose fall to generate symptoms of
sufﬁcient intensity to awaken them.
Why intensively treated patients released epinephrine
and experienced symptoms at lower glucose levels be-
came apparent when Simon Heller and Philip Cryer re-
ported that the body adapts to acute hypoglycemia by
lowering the glucose level at which counterregulatory
hormones are released and symptoms appear the next day
(17). This scenario predicts that recurrent insulin-induced
hypoglycemia would create a vicious cycle, progressively
magnifying the defect in counterregulation and symptom
awareness. They called the phenomenon “hypoglycemia-
associated autonomic failure” (HAAF). Subsequently, Geri
Bolli’s group showed that HAAF could, over time, be
reversed by scrupulous avoidance of hypoglycemia (18).
This is, of course, not easy to achieve in clinical practice.
This counterintuitive observation raised the question,
why would the body adapt to hypoglycemia by suppress-
ing its defense against it? My search for answers led me to
a little-explored path, away from the conventional view of
glucose metabolism—one that led to territory ﬁrst ex-
plored by Claude Bernard long before the discovery of
insulin. Bernard proposed, one and a half centuries ago,
that the control center for glucose homeostasis resides in
the brain (19). A more current stimulus for my change in
direction was a study published by Alan Cherrington’s
laboratory (20). Insulin-induced hypoglycemia was per-
formed in two groups of dogs; in one group glucose was
delivered directly into the vessels perfusing the brain to
prevent glucose from falling in the brain. In these dogs the
rise in epinephrine and glucagon secretion was nearly
abolished, despite hypoglycemia in the rest of the body,
suggesting that the brain is the primary site for hypogly-
cemia detection. This prompted me to ask three basic
questions: 1) Where in the brain is the glucose sensor?
2) What mechanisms does it use to activate hypoglyce-
mic counterregulation? 3) Why does hypoglycemia be-
get hypoglycemia?
WHERE IN THE BRAIN IS THE GLUCOSE SENSOR?
To address this question, I turned to studies performed by
Oomura and coworkers, nearly 40 years ago (21). Oomura
demonstrated the existence of specialized neurons in the
FIG. 1. Intensive insulin treatment alters the glucose threshold for
epinephrine (EPI) release in response to insulin-induced hypoglycemia
in patients with type 1 diabetes (T1DM).
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glucose levels changed. These neurons were predomi-
nantly located in the hypothalamus, a critical brain region
for many basic survival functions such as reproduction,
energy metabolism, and feeding. In particular, they were
concentrated in the ventromedial hypothalamus (VMH), a
brain area that encompasses the ventromedial and arcuate
nuclei. To determine if the VMH was the location of the
brain glucose sensor, Jerry Shulman and I joined forces to
adapt the hypoglycemic clamp, originally developed in
humans for studies in awake, chronically catheterized
rodents. This allowed us to test the effect of selective
bilateral VMH lesions on counterregulatory responses
under identical hypoglycemic conditions in awake, freely
moving rats (22). Hypoglycemia increased glucagon and
epinephrine secretion in sham-operated control rats as
well as in rats with lesions elsewhere in brain. In contrast,
VMH lesions caused a striking reduction in hormonal
responses to hypoglycemia, indicating that the VMH was a
place to explore in more detail. The clinical relevance of
these observations in rodents was subsequently supported
in a 1999 case report of a patient with the same dramatic
suppression of hormonal responses to hypoglycemia in
which sarcoid lesions had destroyed the VMH (23).
The complexity and small size of the VMH meant we
needed a new way to navigate—one that allowed us to
selectively alter the local environment of the VMH. For
this purpose, Walter and Monica Borg conducted experi-
ments in which guide cannulae were inserted in close
proximity to the VMH. After the animals recovered, micro-
dialysis probes were inserted to deliver test substances
directly to the VMH. Hypoglycemic clamp studies could
then be performed while simultaneously manipulating the
local microenvironment of the VMH. In one study, VMH
glucopenia was selectively produced by local delivery of
2-deoxy-glucose (24). This caused glucose to rise in con-
junction with a marked increase in counterregulatory
hormone secretion. Next, D-glucose (metabolically active)
and L-glucose (a metabolically inactive control) were
delivered directly to the VMH to selectively prevent hypo-
glycemia in the VMH, while the rest of the brain and
extra-cerebral tissues were exposed to hypoglycemia (25).
VMH perfusion with D-glucose markedly suppressed both
glucagon and epinephrine release, while inactive L-glucose
control had no effect. Interestingly, VMH perfusion with
L-lactate (but not metabolically inactive D-lactate) also
abolished the hormone response to hypoglycemia (26).
Taken together, the data suggest VMH neurons are critical
for the activation of glucose counterregulation and that
they may act as fuel and not simply as glucose sensors.
It should be emphasized that our data do not mean that
glucose sensing is restricted to neurons in the VMH. The
system is undoubtedly much more complex. Glucose
sensors have been identiﬁed in peripheral tissues, such as
the portal vein and carotid body (27,28), as well as
elsewhere in the brain (29–31). The VMH may act as a
central integrator of glucose-sensing signals that are both
locally generated and come from a network of sensors
widely distributed throughout the body during hypoglyce-
mia. Its function is to integrate this information and to
activate downstream signals to rapidly restore and main-
tain glucose homeostasis.
We next tested whether the capacity of the VMH to
sense hypoglycemia becomes impaired in rats after expo-
sure to antecedent hypoglycemia; rats, like humans, de-
velop defective glucose counterregulation under these
conditions (32). Delivery of 2-deoxy-glucose to block VMH
glucose metabolism in rats exposed to recurrent insulin-
induced hypoglycemia failed to activate glucagon and
epinephrine secretion, whereas in control animals, 2-de-
oxy-glucose, as expected, provoked counterregulatory
hormone secretion (33). These ﬁndings prompted us to
examine the mechanisms used by the VMH to sense
glucose and to determine if they are altered by antecedent
hypoglycemia.
WHAT MECHANISMS DOES THE VMH USE TO
ACTIVATE COUNTERREGULATION?
In vitro electrophysiology studies (34–36) have identiﬁed
two distinct types of glucose-sensing VMH neurons: 1)
glucose-excited (GE) neurons that increase their activity
with a rise in glucose and are suppressed by a fall in
glucose and 2) glucose-inhibited (GI) neurons that de-
crease their activity when glucose rises and increase their
activity when glucose falls. Interestingly, these glucose-
sensing neurons appear to employ mechanisms to detect
glucose excess and deﬁciency that are very similar to
those used in peripheral tissues, such as -cells and
muscle. Current data suggest that GE neurons may sense
glucose via its effects on ATP-sensitive K
 channel (KATP
channel) activity, much like pancreatic -cells (34–36).
Interestingly, VMH neurons express the same SUR1 KIR-
6.2 KATP channel isoform as the pancreatic -cell (37).
VMH GI neurons, on the other hand, may use the AMP
kinase to sense fuel deﬁcit (38,39). This enzyme is regu-
lated by the relative cellular concentrations of AMP and
ATP and functions as a fuel gauge in and outside the brain
(e.g., muscle) to protect against energy depletion (40).
These in vitro ﬁndings prompted us to explore if these
glucose-sensing mechanisms were used by the VMH in
vivo.
KATP channel activity. To evaluate whether KATP chan-
nel activity of VMH neurons alters glucose counterregula-
tion, KATP channel openers (KCOs) (activators), KATP
channel closers (blockers), or vehicle (control) were bi-
laterally microinjected directly into the VMH of awake,
chronically catheterized nondiabetic rats before a hypo-
glycemic clamp study (41,42). VMH microinjection of
diazoxide, a KCO, reduced by 50% the glucose infusion
rate needed to maintain hypoglycemia and increased the
response of both epinephrine and glucagon to hypoglyce-
mia threefold (P  0.05). Similar enhancement of glucose
counterregulation was observed when a SUR1-speciﬁc
KCO was delivered to the VMH instead. Conversely, clo-
sure of VMH KATP channels with the sulfonylurea gliben-
clamide suppressed counterregulatory hormone secretion
during hypoglycemia. Thus, the activity of KATP channels
in VMH neurons, much like in -cells, modulates hormone
responses during hypoglycemia (Fig. 2).
HOW DO CHANGES IN VMH KATP CHANNEL ACTIVITY
MODULATE GLUCOSE COUNTEREGULATION?
To address this issue, we focused on the inhibitory neuro-
transmitter -aminobutyric acid (GABA), based upon the
link between intra-islet GABA inhibitory tone and the
secretion of glucagon (43). Initial studies showed that
acute hypoglycemia rapidly reduced GABA levels in VMH
interstitial ﬂuid, implying that a fall of this inhibitory
neurotransmitter might activate a VMH signal. To test this
hypothesis further, Owen Chan (Yale University, New
Haven, CT) measured GABA levels in VMH interstitial ﬂuid
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hypoglycemia (44). Opening KATP channels with diazoxide
produced a much more pronounced reduction in GABA
levels in VMH interstitial ﬂuid and at the same time
augmented hormone release. Conversely, closure of KATP
channels by local delivery of a sulfonylurea to the VMH
caused a paradoxical increase in VMH GABA levels in
conjunction with suppression of the counterregulatory
hormone response to hypoglycemia (Fig. 2). Furthermore,
modulation of VMH GABA tone using GABAA receptor
agonists suppressed, whereas GABAA receptor antago-
nists augmented, glucagon and epinephrine responses to
hypoglycemia (45). Taken together, it would appear that
KATP channels in glucose-sensing VMH neurons modulate
local GABAergic inhibitory tone, which in turn modulates
the magnitude of the counterregulatory response.
AMP kinase activity. Rory McCrimmon explored the role
of AMP kinase in VMH glucose sensing. For this purpose,
AICAR (5-aminoimidazole-4-carboxamide) was delivered
into the VMH to locally stimulate the enzyme. This in-
creased glucose counterregulation (46). Conversely, he
selectively reduced P	
2 gene expression by 40% in
the VMH using a selective short hairpin RNA (shRNA)
processed in an adeno-associated virus (AAV) (47). This
caused a marked reduction in epinephrine and glucagon
release during hypoglycemia (Fig. 3), suggesting that VMH
AMP kinase activity has an important inﬂuence on the
magnitude of the counterregulatory response, as well. This
conclusion is also supported by in vitro data from Vanessa
Routh’s laboratory demonstrating that the activation of
VMH glucose-inhibited neurons is linked to the activation
of AMP kinase within these neurons (48).
HOW DO THESE STUDIES ALL FIT TOGETHER?
I propose a working model of VMH glucose sensing in
which a downstream VMH signal to promote counterregu-
latory hormone secretion is driven by the simultaneous
activation of AMP kinase in GI neurons as well as by GE
neuron–driven disinhibition of GABA neurons (Fig. 4).
Based on recent data implicating ventromedial nucleus
SF1 glutamate neurons in activating counterregulatory
responses (49), it is intriguing to speculate that ventrome-
dial nucleus SF1 glutamate neurons may be responsible
for generating this downstream signal.
The model predicts that changes in VMH glucose-sens-
ing activity in GI and GE neurons work in concert to
stimulate or inhibit glucose counterregulation. In response
to hyperglycemia, AMP kinase in VMH GI neurons is
suppressed, reducing neuronal activity, and at the same
time KATP channels in GE neurons close and calcium
enters the neuron, stimulating the release of the inhibitory
neurotransmitter GABA, further suppressing the GI neu-
ron. Conversely, hypoglycemia stimulates AMP kinase
activity, stimulating VMH GI neurons, and at the same time
KATP channels open in GE neurons and calcium entry is
reduced, reducing GABA tone, which in turn causes disin-
hibition of VMH GI neurons. Remarkably, this picture
bears a striking resemblance to the crosstalk found in the
islet when blood glucose levels change. The -cell and
glucose-excited neurons have much in common, as do the

-cell and glucose-inhibited neurons.
Corticotropin-releasing factor receptors. As with
most things in biology, the story turns out to be more
complex. VMH neurons are regulated during hypoglycemia
FIG. 2. Changes in VMH KATP channel activity modulate the counter-
regulatory hormone response to hypoglycemia via the local release of
GABA.
FIG. 3. Inhibition of AMPK2 gene expression in the VMH with AAV
RNA interference (AMPK shRNA) reduces glucagon and epinephrine
release during hyperinsulinemic hypoglycemia. The upper panel shows
the distribution of the virus following bilateral VMH microinjections of
a green ﬂuorescent protein (GFP)-tagged AAV-shAMPK; most GFP-
positive neurons are located in the VMH rather than arcuate nucleus
(ARC). (Please see http://dx.doi.org/10.2337/db08-9023 for a high-
quality digital representation of this ﬁgure.).
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cemia provokes stress signals from brain regions outside
of the VMH that modulate its activity via two types of
corticotropin-releasing factor receptors that oppose each
other. The primary stress peptide hormone corticotrophin-
releasing factor (CRF) predominately stimulates VMH
CRF1 receptors and, in turn, counterregulatory responses
(50). Local VMH delivery of a CRF1 receptor antagonist
during hypoglycemia suppresses both epinephrine and
glucagon responses, whereas local VMH microinjection of
CRF stimulates the release of these hormones during
acute hypoglycemia. The stress response also provokes a
counterbalancing stress inhibitory signal urocortin III, a
member of the CRF family of neuropeptides identiﬁed by
Wylie Vale’s laboratory a decade ago (51). Urocortin III is
a selective CRFR2 receptor agonist that is generated in the
medial amygdula and released locally into the VMH, where
it acts to suppress counterregulatory hormone responses
to hypoglycemia. This effect is reversed by the selective
CRFR2 antagonist antisauvagine (52). These observations
are consistent with whole cell–current clamp recordings
in brain slices showing that CRF2 receptor activation
directly lowers the glucose concentration required to
trigger activation of VMH GI neurons. In short, hypoglyce-
mic stress provokes dual modulation of the neuroendo-
crine response via stimulation of endogenous CRF2
(inhibitory) and CRF1 (stimulatory) receptors. Based on
these data, I have expanded my working model to incor-
porate the additional neuronal input to the VMH generated
by the stress pathway during hypoglycemia. This postu-
lated multistep process allows for the full activation of the
VMH downstream neuronal signal stimulating glucose
counterregulation (Fig. 5). How might such a model help
us to understand why hypoglycemia begets hypoglycemia?
WHY DOES HYPOGLYCEMIA BEGET MORE
HYPOGLYCEMIA?
The proposed model of VMH glucose sensing may serve as
a starting point to help us understand why hypoglycemia
begets hypoglycemia. Several putative mechanisms
emerge. Recurrent antecedent hypoglycemia might reduce
VMH KATP channel activity or increase VMH GABA or
urocortin III inhibitory input or suppress VMH AMP kinase
activity. To address these possibilities, we developed an
animal using nondiabetic rats exposed to recurrent ante-
cedent insulin-induced hypoglycemia for 3 h for 3 days.
Typically, this protocol reduces hormonal responses dur-
ing a hypoglycemic clamp study by 50%, much as it does
in humans (17).
Reduced VMH KATP channel activity. To determine
whether KCO delivery to the VMH could reverse defective
glucose counterregulation, rodents exposed to antecedent
hypoglycemia were given bilateral microinjections of ei-
ther diazoxide or vehicle into the VMH, after which they
underwent a hypoglycemic clamp study (41). VMH delivery
of diazoxide or a SUR1-speciﬁc KCO totally reverses the
animal’s defective counterregulatory response (Fig. 6). Pre-
liminary studies suggest that the systemic delivery of KCO
has similar beneﬁcial effects on hormonal responses to
hypoglycemia in animals with impaired glucose counterregu-
lation and thus might have therapeutic beneﬁt in patients
with type 1 diabetes.
Increased VMH GABAergic inhibitory tone. To assess
whether increased VMH GABA tone contributes to the
development of defective counterregulation, we quantiﬁed
the GABA synthetic enzymes GAD65 and GAD67 within the
VMH of rats exposed to recurrent hypoglycemia (53).
These rodents demonstrated a speciﬁc increase in GAD65
gene expression and a ﬁve- to sixfold increase in GAD65
protein expression within the VMH. We also measured
GABA levels in VMH interstitial ﬂuid in rats exposed to
antecedent hypoglycemia. In keeping with the GAD65
protein ﬁndings, basal levels of GABA in VMH interstitial
ﬂuid were threefold higher in the basal state and during
acute hypoglycemia. Furthermore, delivery of a GABAA
receptor antagonist into the VMH of these rats reversed
their defective counterregulatory hormone response (53).
FIG. 4. Working model of VMH glucose sensing. Reciprocal changes in
glucose-excited and glucose-inhibited neurons act in concert to stim-
ulate or inhibit glucose counterregulation when blood glucose rises or
falls.
FIG. 5. Expanded VMH model for activation of glucose counterregula-
tion to include stimulatory and inhibitory input from the CRF family of
neuropeptides. The model posits that hypoglycemia provokes the
activation of AMP kinase in VMH glucose-inhibited neurons. Simulta-
neously, the inhibitory neuronal inputs, urocortin III and GABA, are
suppressed, and the CRF metabolic stress pathway is activated. To-
gether, these changes act in concert to fully activate downstream
neural pathways to restore glucose homeostasis.
FIG. 6. Delivery of KCOs into the VMH reverses the suppressive effect
of antecedent recurrent hypoglycemia on glucagon and epinephrine
secretion. Three groups of rats were studied: control (open bars),
recurrent hypoglycemic (shaded bars), and recurrent hypoglycemic
plus bilateral VMH KCO microinjections (black bars).
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enhance VMH GABAergic inhibitory tone and in turn
impair glucose counterregulation.
Increased VMH CRF2 receptor activity. The role of
altered VMH CRF receptor activity in the pathogenesis of
impaired counterregulation after antecedent hypoglyce-
mia remains to be explored. The possibility that hypogly-
cemia-induced increases in plasma cortisol might be the
driving force (54) led us to study nondiabetic human
subjects in whom antecedent hypoglycemia was produced
with and without concurrent blockade of endogenous
cortisol production using metyrapone (55). We observed
that antecedent hypoglycemia suppressed the epinephrine
response to hypoglycemia the next day regardless of
whether endogenous cortisol production was selectively
suppressed with metyrapone. These observations are most
consistent with rodent data (50,52,56), suggesting that
hypoglycemia-induced alterations in brain CRH receptor
activity rather than increases in plasma cortisol are more
likely to contribute to the pathogenesis of defective coun-
terregulation following antecedent hypoglycemia.
Suppressed VMH AMP kinase activity. To test the
potential role of suppressed VMH AMPK activity in defec-
tive counterregulation, we injected the chemical activator
of AMP kinase, AICAR, into the VMH of rats exposed to
recurrent hypoglycemia (57). This totally reversed the
impaired hormonal response to acute hypoglycemia seen in
these animals, ﬁndings consistent with data demonstrating
impaired hypothalamic AMPK activation in this rodent model
(58). Similar results were also observed in diabetic BB rats, a
model of type 1 diabetes that exhibits a nearly absent
glucagon response to hypoglycemia (59). Chemical activa-
tion of AMP kinase within the VMH increased epinephrine
secretion three- to fourfold during hypoglycemia and unex-
pectedly stimulated glucagon release, implying that this
defect in type 1 diabetes might be reversible as well (unpub-
lished data, R. McCrimmon).
WHY DOES HYPOGLYCEMIA BEGET HYPOGLYCEMIA?
Lessons learned from my journey. One might speculate,
based on our VMH model of glucose counterregulation,
that recurrent hypoglycemia impairs VMH glucose sensing
and signaling by multiple complementary adaptations (Fig.
7), including suppressed VMH AMP kinase activity and
increased activation of inhibitory neuronal circuits, medi-
ated by GABA or CRF receptors. It is noteworthy that
these adaptive responses appear to be reversible, as has
been reported clinically. Most importantly, the proposed
model offers a number of potential therapeutic targets to
reverse the phenomenon in patients with type 1 diabetes.
Of course, we are undoubtedly dealing with a much more
complex system. This should not be a surprise, given that
maintenance of glucose homeostasis is so important to
survival.
WHY WOULD THE BRAIN ADAPT TO RECURRENT
HYPOGLYCEMIA BY BECOMING MORE VULNERABLE
TO IT?
The brain is not as vulnerable as it seems. It may have
adapted to this recent challenge (from an evolutionary
perspective) the best way it can, namely, by becoming
more efﬁcient metabolically, by increasing the transport of
glucose across the blood-brain barrier, and by using alter-
native fuels to glucose. This view is supported by several
observations. Antecedent insulin-induced hypoglycemia
increases brain glucose transport and utilization in rodents
(60–62) and brain glucose uptake in nondiabetic and
diabetic humans rendered hypoglycemic for several days
(63,64). Under conditions of more prolonged glucose
deprivation, the brain most likely adapts to use a number
of alternative fuels to generate ATP, such as the monocar-
boxylic acids lactate, ketone bodies, and acetate. All are
potential energy sources. In starvation, humans can toler-
ate severe hypoglycemia (1 mmol/l) without an impair-
ment of cognitive function by increasing the use of ketone
bodies as an energy source for the brain (65). In keeping
with this scenario, the brain utilization of monocarboxylic
acids appears to be increased in type 1 diabetic patients
receiving intensive insulin therapy (66). Thus, the brain
exposed to antecedent hypoglycemia may adapt, much as
it did long before the discovery of insulin, i.e., when
glucose declined during prolonged starvation.
The adaptation to recurrent hypoglycemia is likely to
serve two basic survival functions, serving initially to
protect the body from the negative consequences of
recurrent stress and serving long term to protect the brain
from fuel deprivation, much like the phenomenon of
preconditioning. The problem is that these beneﬁcial ad-
aptations also act to limit the brain’s ability to detect
reductions in blood glucose. As a result, when it does
sense hypoglycemia, it may be too little, too late.
DO HYPOGLYCEMIA-INDUCED ADAPTATIONS IN BRAIN
FUEL METABOLISM PROTECT IT FROM INJURY?
To examine this question, Ewan McNay tested spatial
memory performance and brain glucose metabolism in
nondiabetic and streptozotocin-induced diabetic rats ex-
posed to hypoglycemia for 3 consecutive days (67). Re-
markably, memory performance improved in both groups
of rats when they were studied at euglycemia the next day,
most likely due to an increase in glucose transport across
the blood-brain barrier. The capacity of antecedent hypo-
glycemia to enhance cognition was, however, limited.
When these animals were exposed to moderately severe
hypoglycemia, the improvement in cognitive performance
could not be sustained. Thus, a point may be reached
when there is need to preserve basic functions (e.g.,
hypothalamic and brainstem activity) at the expense of
more complex functions (e.g., spatial memory). This view
is supported by studies demonstrating that antecedent
hypoglycemia facilitates brainstem neural transmission
during acute hypoglycemia (68).
FIG. 7. Potential adaptive mechanisms for the development of defec-
tive glucose counterregulation based on the proposed VMH glucose-
sensing model, including diminished AMP kinase activity in VMH
glucose-inhibited neurons as well as increased activation of GABA and
CRF2 receptor inhibitory neuronal circuits.
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using a more clinically relevant protocol (69). Hypoglyce-
mia was induced in nondiabetic rats for 3 h once each
week, a pattern similar to that seen in insulin-treated
diabetic patients. Weekly bouts of insulin-induced hypo-
glycemia were initiated at 1 month of age and continued
until the animals were 1 year of age (Fig. 8). Spatial
working memory performance was tested 1 week after the
animal’s last bout of hypoglycemia when they were eugly-
cemic. At 4 months of age the rats exposed to weekly
hypoglycemia, like their counterparts in the short-term
study, performed better during the memory task. After 1
year, while the control animals showed the expected steep
decline in memory performance, this failed to occur in rats
exposed to hypoglycemia. Indeed, they performed like a
4-month-old control animal. These data suggest that there
are marked differences in the immediate consequences of
acute hypoglycemia and the long-term effects of recurrent
hypoglycemia on higher brain function. This conclusion is
consistent with the follow-up analysis of DCCT patients,
nearly two decades after the start of the study (70).
Detailed neuropsychiatric testing (when these patients
were not hypoglycemic) failed to detect cognitive dysfunc-
tion in the intensively treated patients with more frequent
severe hypoglycemia. Although these data are not deﬁni-
tive, they suggest that insulin, as we give it today, really
has two dark sides. From an acute prospective it is the
serious immediate consequences of hypoglycemia, but
over the long haul, for most patients, it is hyper- rather
than hypoglycemia.
VIEW OF GLUCOSE HOMEOSTASIS FROM ACROSS THE
BLOOD-BRAIN BARRIER
For the 85 years since Banting’s landmark discovery, the
regulation of glucose homeostasis has been viewed by the
diabetes world from an islet-centric perspective. Bernard’s
vision of the brain as the master control site of glucose
homeostasis has, for the most part, been abandoned. My
journey across the blood-brain barrier has taught me that
Bernard’s vision should not be forgotten. I believe we
evolved dual control centers for the regulation of glucose
homeostasis, the islet and the brain, and that they are
wired together and connected with the rest of the body to
more precisely regulate blood glucose as fuel demands
change.
I believe the brain, and the VMH in particular, is the
dominant control center initiating counterregulatory re-
sponses when blood glucose falls below baseline. This
view is consistent with the brain’s immediate dependence
on glucose as an energy source and the marked differences
in the concentration of glucose within brain interstitial
ﬂuid compared with levels elsewhere in the body. How-
ever, dual control is more effective. The islet supports the
VMH by reducing its secretion of insulin and by working in
concert with the VMH to increase glucagon secretion (Fig.
9). On the other hand, the islet serves as the dominant
sensor when blood glucose rises, by virtue of its ability to
increase its secretion of insulin and to reduce its secretion
of glucagon. However, once again dual control is more
effective in restoring glucose homeostasis (Fig. 10). The
brain receives neural and hormonal signals from the gut
that promote insulin secretion as well as glucose storage
in the liver (71,72). The brain may also receive a signal
from the islet to facilitate the suppression of hepatic
glucose production (73) as well as glucagon secretion.
Again, the islet and VMH are working synergistically.
How did such a dual glucose sensor system evolve?
There are lessons we can learn from the fruit ﬂy. The cells
that produce insulin in the fruit ﬂy, like other inverte-
brates, are located in the brain (74). These insulin-
secreting neurons communicate directly with cells that
secrete an anti-insulin hormone that has effects similar to
glucagon (75). Thus, the ancestral home of the islet and
the regulation of glucose homeostasis most likely resided
FIG. 8. Inﬂuence over time of once weekly bouts of insulin-induced
hypoglycemia (3 h) on memory performance in nondiabetic rats.
Animals exposed to recurrent hypoglycemia (RH) and those given
saline injections (controls) were tested 1 week after their last injec-
tion of insulin or saline when they were euglycemic.
FIG. 9. The brain and islet work in concert to regulate glucose
homeostasis. During hypoglycemia the brain serves as the dominant
control center.
FIG. 10. The brain and islet work in concert to regulate glucose
homeostasis. During hyperglycemia the islet serves as the dominant
control center.
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more advantageous for the islet to move from the brain to
an area closer to the liver, the site where glucose is stored.
Nevertheless, one can imagine that it would have been
crucial for survival to retain glucose-sensing neurons with
characteristics similar to - and 
-cells in the VMH to
directly monitor minute-to-minute changes in brain glu-
cose availability more closely. This might be particularly
important given that the levels of glucose in brain intersti-
tial ﬂuid are only a small fraction (25%) of those bathing
peripheral tissues. Thus, I believe it was essential to retain
glucose sensors in the VMH; only a site within the brain
can provide a truly accurate assessment of its energy
supply. A peripheral glucose sensor exposed to much
higher glucose levels during hypoglycemia probably
couldn’t do the job as well. This is crucial since the brain
is the only organ that must have glucose to meet its
immediate needs. As a result, insulin-induced hypoglyce-
mia is a brain-speciﬁc complication.
POSTSCRIPT
I’d like to end my journey across the blood-brain barrier
with a postscript. When I began my research career, I was
taught that there were speciﬁc organs that responded to
insulin and that the brain was not one of them. This view
is now being challenged on many fronts. Dan Porte, Steve
Woods, and Michael Schwartz have established that insu-
lin modulates satiety by acting on the hypothalamus (76).
Rossetti and coworkers (73) suggest the existence of an
insulin-brain-liver connection that regulates glucose me-
tabolism. Furthermore, our preliminary studies indicate
that delivery of small amounts of insulin directly into the
hippocampus of nondiabetic rats, a brain region critical
for learning and memory and rich in insulin receptors and
GLUT4 (77), signiﬁcantly improves cognitive performance
and stimulates local brain glucose metabolism. This effect
is impaired in insulin-resistant rats with diet-induced obe-
sity, suggesting a potential link between defective insulin-
stimulated glucose metabolism in the hippocampus and
the increased risk of cognitive impairment seen in type 2
diabetes.
These observations raise another important question,
namely, could insulin also act directly on the VMH, altering
its capacity to sense fuel deﬁcit? This possibility is sup-
ported by evidence that VMH neurons express insulin
receptors and that insulin alters the ﬁring rate of VMH
glucose-sensing neurons in vitro (78). It is intriguing to
speculate that we evolved a dual glucose-sensing system
based in the VMH and islet designed to defend against
hypoglycemia in the setting in which it originally occurred,
namely during prolonged starvation, a time when both
glucose and insulin levels fall simultaneously. Thus, we
may not have optimally adapted to insulin-induced hypo-
glycemia, a danger rarely, if ever, encountered before
Banting (Fig. 11). During insulin-induced hypoglycemia,
the 
-cell sees a drop in local islet insulin in spite of the
rise in systemic insulin levels, given the suppression of
endogenous insulin production. On the other hand, the
VMH gets a very different message, namely, a feeding
signal: insulin. How this might impact on the homeostatic
response to hypoglycemia in nondiabetic and diabetic
individuals’ disease warrants careful scrutiny. It is possi-
ble that insulin-induced hypoglycemia may limit the capac-
ity of the body to defend against the challenge of acute
hypoglycemia. A maximal response to insulin-induced
hypoglycemia may require both the islet and the VMH to
see a drop in insulin concentration.
Six years ago in my American Diabetes Association
president’s address, I challenged the diabetes community
to think beyond the barriers—beyond glucose. I suggested
that our journey would require engaging scientists from
many different disciplines, people not currently working in
diabetes. I challenge you again to think beyond the islet
and to engage the burgeoning world of neuroscience.
These efforts will help us unravel not only hypoglycemia
but also such problems as obesity, Alzheimer’s disease,
and perhaps even type 2 diabetes.
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